Maze Therapeutics, Inc. (MAZE)
$26.66-3.75%Close
BUYRECOVERY · day 16
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $1.5B
- Beta
- 2.15
- P/E (TTM)
- -9.73
- Short % float
- 41.09%
- Days to cover
- 6.1
- SI change
- +15.6%
- 1W
- +0.87%
- 1M
- +8.07%
- vs SPY 1W
- +1.01%
- vs SPY 1M
- +5.56%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 4
- VALUE
- 2
- GROWTH
- 17
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-21.0%
REV YoY-
ROE-34.9%
EPS YoY-
ROA-25.1%
GROSS95
OP-728
NET-668
[VALUATION]
P/E TTM-9.73
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B3.47
P/FCF-
EV/EBITDA-10.26
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E13.33
ALTMAN Z-
CURR RATIO18.31
ND/EBITDA-
BETA2.15
Company news
FAQ
- What is LOPJLB’s current signal on MAZE?
- LOPJLB’s latest quantitative signal on Maze Therapeutics, Inc. (MAZE) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is MAZE in?
- Maze Therapeutics, Inc. (MAZE) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Maze Therapeutics, Inc. (MAZE) do?
- Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral…